Blood pressure and kidney study for prostate cancer treatment
Part of Brain & nervous system, Cancer, Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how a common prostate cancer treatment called androgen deprivation therapy (ADT) affects blood pressure and kidney function. It may help doctors understand and manage these side effects better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 40 years old or older.
- Your blood pressure should be below 140/90 mmHg.
- Your fasting blood sugar should be under 126 mg/dL.
- If you are healthy, your testosterone level should be at least 400 ng/dL.
- You must be a nonsmoker and not taking heart or blood pressure medications.
- You need to be willing to receive ADT (if you have prostate cancer) or be part of the comparison group.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a short course of hormone therapy (androgen deprivation therapy) for men with a certain type of prostate cancer that is considered high-risk. The goal is to see if a shorter treatment period can still control the cancer while reducing side effects.
This study tests whether a team of doctors, nurses, and other specialists can help reduce the risk of heart problems in men with prostate cancer who are on hormone therapy (ADT). It focuses on providing extra support for heart health.
This trial tests a new treatment called CTX340 for high blood pressure that is hard to control even with multiple medications. The study aims to see if it is safe and effective.
This study checks how men starting hormone therapy (ADT) for prostate cancer are doing with their heart health. It offers follow-up visits at the cancer center to track blood pressure and lab results, with the goal of catching any heart-related issues early.
This study looks at how hormone therapy (ADT) affects muscle aging in older men with prostate cancer. It aims to understand why muscles weaken during this treatment, which could lead to better ways to protect muscle health in the future.
This study is for men with advanced prostate cancer that stopped responding to one hormone therapy and will be starting another. Researchers will collect blood samples to look for markers that might explain why the resistance happens.
Hear when a new Androgen Deprivation Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.